Apr 7, 2023 | Blog, Shareholder Investigations
Investors of Ascendis Pharma A/S Stock Who Have Suffered Losses of At Least $50,000 Encouraged to Contact Kehoe Law Firm, P.C. – ASND
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ascendis Pharma A/S (“Ascendis,” “Ascendis Pharma” or the “Company”) (NASDAQ: ASND).
INVESTORS OF ASCENDIS PHARMA STOCK WHO HAVE SUFFERED FINANCIAL LOSSES OF $50,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR ASCENDIS SECURITIES.
Investors should be aware that on April 3, 2023, Ascendis “. . . announced that the U.S. Food & Drug Administration (‘FDA’) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (‘NDA’) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter.”
ASCENDIS PHARMA SHAREHOLDERS WHO SUFFERED SIGNIFICANT LOSSES ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Mar 23, 2023 | Blog, Shareholder Investigations
Investors of Coinbase Stock With At Least $250,000 in Losses Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Coinbase Global Inc. (“Coinbase” or the “Company”) (NASDAQ: COIN).
INVESTORS OF COINBASE STOCK WHO HAVE SUFFERED LOSSES OF $250,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR COINBASE SECURITIES.
Coinbase recently reported that “[o]n March 22, 2023, Coinbase . . . received a ‘Wells Notice’ from the Staff . . . of the Securities and Exchange Commission . . . stating that the Staff has advised the Company that it made a ‘preliminary determination’ to recommend that the SEC file an enforcement action against the Company alleging violations of the federal securities laws, including the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’), and the Securities Act of 1933, as amended (the ‘Securities Act’).”
Further, Coinbase reported that “[b]ased on discussions with the Staff, the Company believes these potential enforcement actions would relate to aspects of the Company’s spot market, staking service Coinbase Earn, Coinbase Prime and Coinbase Wallet. The potential civil action may seek injunctive relief, disgorgement, and civil penalties.”
On this news, Coinbase stock was down more than 17% during intraday trading on March 23, 2023.
COINBASE SHAREHOLDERS WHO HAVE SUFFERED FINANCIAL LOSSES OF AT LEAST $250,000 ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Mar 13, 2023 | Blog, Shareholder Investigations
BigBear.ai Investors Who Held GigCapital4 Stock Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of GigCapital4, Inc. (“GigCapital4), now known as BigBear.ai Holdings, Inc. (“BigBear”) (NYSE: BBAI), breached their fiduciary duties to GigCapital4 and its shareholders.
On December 7, 2021, BigBear announced the completion of the “business combination” with Special Purpose Acquisition Company (“SPAC”) GigCapital4, which was approved on December 3, 2021 at a Special Meeting of GigCapital4’s stockholders.
The investigation primarily concerns whether GigCapital4 breached its fiduciary duties to GigCapital4 and its shareholders by not providing relevant information to GigCapital4 shareholders prior to the merger.
INVESTORS OF BIGBEAR STOCK WHO HELD GIGCAPITAL4 SHARES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR BIGBEAR/GIGCAPITAL4 SECURITIES.
BIGBEAR SHAREHOLDERS WHO HELD GIGCAPITAL4 STOCK ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Feb 24, 2023 | Blog, Shareholder Investigations
Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics (“Nektar” or “Nektar Therapeutics”) (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.
The investigation concerns whether members of Nektar’s board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.
INVESTORS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR NKTR STOCK SINCE AT LEAST JUNE 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR NKTR SECURITIES.
SHAREHOLDERS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR STOCK SINCE AT LEAST JUNE 2022 ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Feb 24, 2023 | Blog, Shareholder Investigations
Investors of Fulcrum Therapeutics Stock Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fulcrum Therapeutics, Inc. (“Fulcrum” or “Fulcrum Therapeutics”) (NASDAQ: FULC).
On February 24, 2023, shares of Fulcrum Therapeutics stock closed down more than 56%, after Fulcrum ” . . . announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease. The [FDA] indicated that it would provide a formal Clinical Hold Letter to the company within 30 days.”
Fulcrum Therapeutics also reported that “[t]he clinical hold was initiated by the [FDA] due to previously reported preclinical data. Fulcrum will suspend dosing in the Phase 1b trial of FTX-6058 and intends to work diligently with the [FDA] to resolve the hold as soon as possible.”
INVESTORS OF FULCRUM THERAPEUTICS STOCK WHO HAVE SUFFERED LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR SECURITIES.
SHAREHOLDERS OF FULCRUM ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Feb 21, 2023 | Blog, Shareholder Investigations
Silvergate Capital Investors Who Have Held Silvergate Stock Since At Least November 14, 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Silvergate Capital Corporation (“Silvergate” or “Silvergate Capital”) (NYSE: SI) breached their fiduciary duties to Silvergate and its shareholders.
The investigation concerns whether Silvergate Capital’s board failed to disclose material information, including whether Silvergate misled investors and failed to disclose that (i) Silvergate’s platform lacked sufficient controls and procedures to detect instances of money laundering; (2) Silvergate’s customers had engaged in money laundering in amounts exceeding $425 million; and (3) as a result of the foregoing, Silvergate was reasonably likely to receive regulatory scrutiny and face damages, including penalties and reputational harm; and whether statements about Silvergate Capital’s business, operations, and prospects lacked a reasonable basis.
On November 15, 2022, Marcus Aurelius Research stated that recently-revealed Silvergate bank records showed $425 million in transfers to South American money launderers. On November 17, 2022, The Bear Cave reported on several companies with potential exposure to the recently collapsed cryptocurrency exchange FTX, including Silvergate. On January 5, 2023, multiple media reports indicated that Silvergate customers withdrew around $8.1 billion in digital-asset deposits in the fourth quarter of 2022, causing Silvergate to sell assets at a steep loss and fire 40 percent of its staff.
SILVERGATE CAPITAL INVESTORS WHO HAVE HELD THEIR SILVERGATE STOCK SINCE AT LEAST NOVEMBER 14, 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR SECURITIES.
SHAREHOLDERS OF SILVERGATE WHO HAVE HELD THEIR STOCK SINCE AT LEAST NOVEMBER 14, 2022 ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
